Join
Live feed
·
PRReleasevia Quantisnow
Moderna Inc. logo

Moderna's Investigational Therapeutic for Methylmalonic Acidemia (mRNA-3705) Selected by U.S. Food & Drug Administration for START Pilot Program

ByQuantisnow·Wall Street's wire, on your screen.
MRNA· Moderna Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track MRNA (Moderna Inc.) and more on Quantisnow.